HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection

被引:110
作者
Ruiz, L [1 ]
Carcelain, G
Martínez-Picado, J
Frost, S
Marfil, S
Paredes, R
Romeu, J
Ferrer, E
Morales-Lopetegi, K
Autran, B
Clotet, B
机构
[1] Univ Autonoma Barcelona, Hosp Germans Trias & Pujol, IrsiCaixa Fdn, Retrovirol Lab, Barcelona 08916, Spain
[2] Univ Autonoma Barcelona, Hosp Germans Trias & Pujol, HIV Unit, Barcelona 08916, Spain
[3] Hop La Pitie Salpetriere, UMR CNRS 7627, Lab Immunol Cellulaire, Paris, France
[4] Ctr HIV Res, Edinburgh, Midlothian, Scotland
关键词
chronic HIV infection; HAART; HIV dynamics; HIV-specific T cell response; structured treatment interruption;
D O I
10.1097/00002030-200106150-00001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To evaluate whether controlled re-exposures to autologous HIV-1 could boost HIV-specific immunity and limit virus replication in patients with chronic HIV-1 infection. Patients and design: Subjects with at least 2 years virus suppression during antiretroviral therapy and a CD4:CD8 ratio > 1 were randomly assigned to interrupt highly active antiretroviral treatment (HAART) three times (n =12) or to continue their previous HAART (n = 14). Results: In 10/12 interrupter patients a rebound of HIV-1 RNA was detected in all three structured treatment interruptions (STI). Plasma virus doubling time was shorter during the first STI than in the second and third STI, corresponding to an average 13% reduction in viral basic reproductive rate. However, the mean time before plasma viral load rose to > 50 copies/ml was significantly shorter in the second and third STI. The average frequency of HIV-specific CD8 T cells in the interrupter patients at the end of the third STI cycle was significantly higher compared with the baseline and the end of the first STI. A substantial increase in HIV-specific CD8 T cell frequencies was found in four interrupter patients, whereas there were no changes in all 14 non-interrupter individuals. A weak p24-specific T helper response developed in 5/12 interrupter patients compared with no response in non-interrupters, but these responses were transient and disappeared rapidly. Conclusion: The increase in the control of viral replication, and positive effects of STI on immune responses in this population should encourage the further development of HIV-specific immune-based therapeutic strategies. (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:F19 / F27
页数:9
相关论文
共 35 条
[1]   Impact on the immune system of undetectable plasma HIV-1 RNA for more than 2 years [J].
Arnó, A ;
Ruiz, L ;
Juan, M ;
Zayat, MK ;
Puig, T ;
Balagué, M ;
Romeu, J ;
Pujol, R ;
O'Brien, WA ;
Clotet, B .
AIDS, 1998, 12 (07) :697-704
[2]   Positive effects of combined antiretroviral therapy on CD4(+) T cell homeostasis and function in advanced HIV disease [J].
Autran, B ;
Carcelain, G ;
Li, TS ;
Blanc, C ;
Mathez, D ;
Tubiana, R ;
Katlama, C ;
Debre, P ;
Leibowitch, J .
SCIENCE, 1997, 277 (5322) :112-116
[3]   Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection [J].
Carcelain, G ;
Tubiana, R ;
Samri, A ;
Calvez, V ;
Delaugerre, C ;
Agut, H ;
Katlama, C ;
Autran, B .
JOURNAL OF VIROLOGY, 2001, 75 (01) :234-241
[4]   Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study [J].
Carr, A ;
Samaras, K ;
Thorisdottir, A ;
Kaufmann, GR ;
Chisholm, DJ ;
Cooper, DA .
LANCET, 1999, 353 (9170) :2093-2099
[5]   Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy [J].
Dalod, M ;
Harzic, M ;
Pellegrin, I ;
Dumon, B ;
Hoen, B ;
Sereni, D ;
Deschemin, JC ;
Levy, JP ;
Venet, A ;
Gomard, E .
JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (01) :61-69
[6]   HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression [J].
Davey, RT ;
Bhat, N ;
Yoder, C ;
Chun, TW ;
Metcalf, JA ;
Dewar, R ;
Natarajan, V ;
Lempicki, RA ;
Adelsberger, JW ;
Millers, KD ;
Kovacs, JA ;
Polis, MA ;
Walker, RE ;
Falloon, L ;
Masur, H ;
Gee, D ;
Baseler, M ;
Dimitrov, DS ;
Fauci, AS ;
Lane, HC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (26) :15109-15114
[7]   Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy [J].
Finzi, D ;
Blankson, J ;
Siliciano, JD ;
Margolick, JB ;
Chadwick, K ;
Pierson, T ;
Smith, K ;
Lisziewicz, J ;
Lori, F ;
Flexner, C ;
Quinn, TC ;
Chaisson, RE ;
Rosenberg, E ;
Walker, B ;
Gange, S ;
Gallant, J ;
Siliciano, RF .
NATURE MEDICINE, 1999, 5 (05) :512-517
[8]   Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy [J].
Furtado, MR ;
Callaway, DS ;
Phair, JP ;
Kunstman, KJ ;
Stanton, JL ;
Macken, CA ;
Perelson, AS ;
Wolinsky, SM .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (21) :1614-1622
[9]   Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy [J].
García, F ;
Plana, M ;
Vidal, C ;
Cruceta, A ;
O'Brien, WA ;
Pantaleo, G ;
Pumarola, T ;
Gallart, T ;
Miró, JM ;
Gatell, JM .
AIDS, 1999, 13 (11) :F79-F86
[10]  
Gray CM, 1999, J IMMUNOL, V162, P1780